ZMapp antibody delivered by viral vector protects against Ebola infection
New Rochelle, NY, March 8, 2018–A new study comparing the effectiveness of individual ZMapp antibodies versus a cocktail of antibodies, administered to mice using recombinant adeno-associated virus (rAAV) delivery vectors, showed the ability to achieve 100% protection against infection by Ebola virus. The study, which reported the best results using a single rAAV-delivered antibody, is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until April 8, 2018.
Bruno Gaillet, University Laval (Quebec, Canada) and coauthors from National Research Council Canada (Montreal), Public Health Agency of Canada and University of Manitoba (Winnipeg), University of Pennsylvania (Philadelphia), and McGill University (Montreal) coauthored the article entitled "Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections."
The researchers evaluated the therapeutic effectiveness of three ZMapp antibodies (c2G4, c4G7, and c13C6) and different doses and various routes of administration (intravenous, intramuscular and intranasal). They also compared different doses of the individual antibodies to the effectiveness of the three-antibody cocktail.
"Vectored antibody delivery has the potential to revolutionize how we respond to emerging pathogens like Ebola virus disease," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "Professor Gaillet's work provides vital proof of this concept, which could greatly aid global preparedness for the next outbreak."
Research reported in this publication was supported by the National Institutes of Health under Award Numbers R01 AR43623 R21 AR049606, R01 AR048566, R01 AR057422, and R01 AR051085. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101